Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZHONGCHAOZCMD -4.68%47 EBITDA Margin % is -89.61% as of Dec. 2025. GuruFocus rates ZCMD with a GF Score™ of 47/100 and a GF Value™ of $114.09 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 671 Healthcare Providers & Services companies, ZHONGCHAO ranks worse than 88.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ZHONGCHAO's EBITDA for the
six
months ended in Dec. 2025 was $-5.17 Mil. ZHONGCHAO's Revenue for the
six
months ended in Dec. 2025 was $5.77 Mil. Therefore, ZHONGCHAO's EBITDA margin for the quarter that ended in Dec. 2025 was -89.61%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ZHONGCHAO EBITDA Margin % Related Terms
ZHONGCHAO EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ZHONGCHAO's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZCMD vs ACON, BRGX, MGRX: EBITDA Margin % Comparison
For the Health Information Services subindustry, ZHONGCHAO's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZHONGCHAO EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ZHONGCHAO's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ZHONGCHAO's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZHONGCHAO (ZCMD) has a EBITDA Margin % of -89.61% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZHONGCHAO and its competitors. According to the industry distribution chart, ZHONGCHAO ranks #597 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 89%.
Is ZHONGCHAO's EBITDA Margin % too high?
ZHONGCHAO's current EBITDA Margin % is -89.61%. Based on the distribution chart, ZHONGCHAO ranks #597 out of 671 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ZHONGCHAO has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ZHONGCHAO's EBITDA Margin % compare to ACON and BRGX?
According to the Healthcare Providers & Services industry distribution chart, ZHONGCHAO ranks #597 out of 671 companies for EBITDA Margin %. This places ZHONGCHAO in the lower half of its industry. The industry median EBITDA Margin % is 10.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.09, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ZHONGCHAO and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZHONGCHAO's current EBITDA Margin % is -89.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZHONGCHAO stock overvalued right now?
Based on GuruFocus' analysis, ZHONGCHAO (ZCMD) is currently considered Possible Value Trap. The stock's GF Value™ is $114.09, compared to a current price of $0.92 — trading 99.2% below its estimated fair value. The current EBITDA Margin % is -89.61%. ZHONGCHAO's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ZHONGCHAO (ZCMD), the current EBITDA Margin % is -89.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ZHONGCHAO (ZCMD) Overvalued in 2026?
Based on GuruFocus' analysis, ZHONGCHAO stock appears to be undervalued.
The current stock price of $0.92 is trading 99.2% below its estimated GF Value™ of $114.09.
GuruFocus considers ZHONGCHAO to be Possible Value Trap.
Key valuation signals for ZCMD:
EBITDA Margin %: -89.61%
GF Value™: $114.09 vs. price of $0.92 (99.2% below fair value)
No single metric tells the full story. See the ZCMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
47GF Score
Get the complete analysis for ZCMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZCMD has been successfully added to your 
